Katy Burris, MD
Dermatology · New York, NYNPI 1629242144
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Pfizer at 59.5% of the total. Reporting peaked in 2021 at $5,493 and has fallen 92.1% since, to $436 in 2025.
Across 67 payments — averaging $136.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5K
- E.r. Squibb & Sons, L.L.C.$2K
- AbbVie$695
- Johnson & Johnson$158
- Lilly USA, LLC$136
- Incyte Corporation$73
- plus $427 from 10 others
What the payments were for
- Consulting fees$2,20524%
- Speaking & faculty fees$5,40059%
- Food & beverage$1,43916%
- Education$801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 3 | $5,430 |
| E.r. Squibb & Sons, L.L.C. | 1 | $2,205 |
| AbbVie | 30 | $695 |
| Johnson & Johnson | 5 | $158 |
| Lilly USA, LLC | 6 | $136 |
| Incyte Corporation | 3 | $73 |
| Sun Pharmaceutical Industries Inc. | 3 | $73 |
| Galderma Laboratories, L.p. | 3 | $69 |
| LEO Pharma Inc. | 3 | $62 |
| Amgen | 2 | $53 |
| Sanofi | 2 | $44 |
| Arcutis Biotherapeutics, Inc. | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $22 |
| Organon | 1 | $15 |
| Novartis | 1 | $13 |
How this compares
$9,124 in reported general payments places this provider in the 70th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 20 | $76,655 |
| Dupixent PenDupilumab | 18 | $71,344 |
| Clobetasol Propionate | 88 | $4,348 |
| Acitretin | 13 | $3,103 |
| Metronidazole | 23 | $1,808 |
| Fluocinonide | 39 | $1,734 |
| Tacrolimus | 17 | $1,356 |
| Tretinoin | 16 | $1,244 |
| Dutasteride | 24 | $1,126 |
| Ketoconazole | 44 | $806 |
| Minoxidil | 68 | $743 |
| Clindamycin Phosphate | 18 | $704 |
| Triamcinolone Acetonide | 77 | $697 |
| Finasteride | 26 | $676 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 12 | $658 |
Paid to pharmacies, not to this prescriber.
Other dermatology in New York
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Joshua ZeichnerNew York$2.1M
- Emma GuttmanNew York$1.7M
- George HanNew York$1.6M
- Amy SpizuocoNew York$1.3M
- Andrew AlexisNew York$834K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.